伊立替康和拓扑替康二线治疗小细胞肺癌的临床效果比较

Comparative study on the efficacy of Irinotecan or topotecan as a second-line monotherapy for small cell lung cancer

目的：比较单药伊立替康（CPT-11）和拓扑替康（TPT）二线治疗小细胞肺癌的效果不良反应.方法：46例复发性小细胞肺癌患者分CPT-11组（24例）和TPT组（22例）进行治疗,CPT-11组以300 mg/m2第一天静脉注射,TPT组以1.5 mg/m2第1~5天经脉注射,以3周为1个周期,均化疗2~6个周期,比较两组的近期效果、远期效果和不良反应情况.结果：CPT-11和TPT有效率分别为33.3%和27.2%,两组有效率比较差异无统计学意义（P〉0.05）;两组进展时间（mTTP）分别为（11.3±5.94）周和（12.4±6.23）周,生存时间分别为（25.3±6.11）周和（24.3±5.77）周,两组进展时间和生存时间比较差异无统计学意义（P〉0.05）;两组的不良反应分析发现CPT-11组延迟性腹泻发生率显著性高于TPT组（P〈0.05）,其他不良反应两组比较差异无统计学意义（P〉0.05）.结论：单药CPT-11和TPT二线治疗小细胞肺癌疗效相似,不良反应相当,且均为患者耐受.

Objective To compare the efficacy and toxicity of CPT - 11 and TPT as second - line monotherapy for small cell lung canc- er. Methods Forty - six case of recurrent small cell lung cancer were enrolled,24 cases were treated with CPT - 11 （ CPT - 11,300mg/ m2 ,d1 ） and 22cases were treated with TPT （TPT, 1.5mg/m2,dl ~ d5 ）; to observe and compare the respond rates, time to progression （TIP） ,survive time（ST） and adverse events between the two groups. Results the response rates of CPT-II and TPT were 33.3% and 27.2%, respectively, no significance was found between the two groups （ P 〉 0. 05 ） ; the mean TIP of CPT - 11 and TPT were 11.3 ± 5.94 weeks and 12. 4 ± 6. 23weeks, the mean ST were 25.3 ± 6. 11 weeks and 24. 3 ± 5. 77weeks, no significances on TIP and ST were found be- tween the two groups （ P 〉 0. 05 ）. Toxicity analysis showed that the tardily diarrhea rate of CPT - 11 group was significantly higher than that in TPT group（P 〈0. 05） ,and no other significance on toxicity were found between the two groups（P 〉0.05）. Conclusion The efficacy of CPT - 11 and TPT were similar as a second - line monotherapy for small cell lung cancer, and their toxicity are also showed no signifi- canees, and all the toxicity can be tolerated by the patients.